[Form 3] Tharimmune, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

James Gordon Liddy filed an Initial Statement on Form 3 reporting his beneficial ownership in Tharimmune, Inc. (THAR). The filing, tied to an event dated 06/11/2025, shows a stock option granting the right to purchase 50,000 shares of common stock at an exercise price of $1.33 per share. The reporting person is identified as a Director. The explanatory note states that 25,000 options vested on the date of grant and the remaining 25,000 vest on 08/04/2026. The form is signed by the reporting person on 08/22/2025. The ownership is reported as direct.

Insights

Financial Analyst

TL;DR: Director received 50,000 stock options at $1.33, half vested immediately; disclosure is routine and not materially dilutive for most investors.

The grant gives the director economic exposure linked to common stock performance. With an exercise price of $1.33 and 25,000 shares vested immediately, the award aligns management and shareholder interests. Based solely on the filing, there is no information on total outstanding shares, so potential dilution or payoff cannot be quantified. This disclosure is standard Section 16 reporting for insider equity grants.

Corporate Governance Expert

TL;DR: Routine insider grant disclosed promptly; vesting split signals retention intent but contains no governance concerns on its face.

The filing identifies the reporting person as a director and shows a retention/compensation element via a two-step vesting schedule (25,000 vested at grant, 25,000 vesting 08/04/2026). Such schedules are common to promote continued service. The form provides required transparency under Section 16 but includes no additional governance details like board approvals or related-party considerations.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Liddy James Gordon

(Last) (First) (Middle)

C/O THARIMMUNE, INC.

34 SHREWSBURY AVE., SUITE 1C

(Street)

RED BANK NJ 07701

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/11/2025

3. Issuer Name and Ticker or Trading Symbol
Tharimmune, Inc. [ THAR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	08/04/2035	Common Stock	50,000	$1.33	D

Explanation of Responses:

1. 25,000 of the options vest on date of grant and 25,000 vest on August 4, 2026.

	/s/ James Gordon Liddy	08/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did James Gordon Liddy report on Form 3 for THAR?

He reported a stock option to buy 50,000 shares of Tharimmune common stock at an exercise price of $1.33 per share.

When was the event triggering the Form 3 reported for THAR?

The Date of Event Requiring Statement is 06/11/2025.

What is the vesting schedule for the options reported by James Gordon Liddy?

25,000 options vested on the date of grant and 25,000 vest on 08/04/2026.

What role does the reporting person hold at Tharimmune (THAR)?

The filing identifies the reporting person as a Director of Tharimmune.

When was the Form 3 signed by the reporting person?

The signature date on the form is 08/22/2025.